Science

OUR SERVICES

We provide consulting and research services in IgA Nephropathy in the following areas:

  • Consultation regarding novel therapeutics for IgA nephropathy

The combination of these two assays have been demonstrated to disease-specific markers for IgA nephropathy. Currently the use of these assays is for research purposes only.

Scientific Literature:

Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLoS ONE. 13(1): e0190967, 2018.

 

AUTOANTIBODY ASSAY

Assay for autoantibody specific for galactose-deficient IgA1
(anti-Gd-IgA1 autoantibody)

This assay is based on the original discovery in Dr. Novak's group at UAB of the presence of autoantibodies in the serum of patients with IgA nephropathy. These autoantibodies are specific for galactose-deficient IgA1. The assay is an ELISA-based assay that has been extensively used in Dr. Novak's research laboratory and tested with several different patient cohorts.

Scientific Literature about our assay:


Aberrantly glycosylated IgA1 in IgA  nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest. 119, 1668-1677, 2009.

The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol. 22, 1795-1803, 2011. 

Autoantibodies specific for galactose-deficient IgA1 associate with disease progression in IgA nephropathy. J. Am. Soc. Nephrol. 23, 1579-1587, 2012.

Biomarkers in IgA nephropathy: Relationship to pathogenetic hits. Expert Opin. Med. Diagn. 7, 615-627, 2013.

IgA nephropathy. New England Journal  of Medecine. 368, 2402-2414, 2013.

 
Pipetting Samples

GALACTOSE-DEFICIENT IGA1 ASSAY

ELISA for galactose-deficient IgA1

We also provide an assay that measures the extent of IgA1 galactose deficiency. This assay has been used as a means to determine serum levels of galactose-deficient IgA1. The use of this assay established that serum levels of galactose-deficient IgA1 are elevated in patients with IgAN and predict disease progression.

Scientific Literature about this assay:

Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.  Kidney Int.  71, 134-138, 2007.

Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J. Am. Soc. Nephrol. 19, 1008-1014, 2008.

Level of galactose-deficient IgA1 in sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 82, 790-796, 2012.

Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. PLoS ONE. 13(1): e0190967, 2018.

 

Statement Regarding Financial Conflict of Interest for Research Funded Under PHS Grants:

Reliant Glycosciences, LLC takes seriously each potential Conflict of Interest that could affect the integrity of any Public Health Service (PHS)-funded research that is performed by its employees and sub-recipients. As a result, and in compliance with federal law and regulations, Reliant Investigators shall not participate in any PHS-funded Research if he or she has a Financial Conflict of Interest (FCOI) that could influence the design, conduct, or reporting of such research activity. Reliant will take immediate action under this policy to manage, reduce, or eliminate any such Conflict of Interest. As set forth herein, all PHS-funded Research undertaken at Reliant shall be conducted in full compliance with this policy and with all applicable federal and state laws pertaining to financial conflicts of interest, including, without limitation, Title 42 Code of Federal Regulations (CFR) Part 50 Subpart F for grants and cooperative agreements and Title 45 CFR Part 94 for Research contracts (collectively, FCOI Regulations). Investigators failing to comply with all FCOI Regulations shall be subject to sanctions, up to and including termination of employment.